Oculis Holding AG (OCS) Total Debt (2021 - 2022)

Oculis Holding AG's (OCS) quarterly Total Debt came in at $127.1 million in Q4 2022, up 3.26% year-on-year from $123.1 million in Q4 2021, and up 3.26% quarter-over-quarter from $123.1 million in Q4 2021.

Oculis Holding AG (OCS) Total Debt (2021 - 2022) Analysis & Trends

Oculis Holding AG's Total Debt history runs 2 years deep, the most recent figure standing at $127.1 million for Q4 2022.

  • On a quarterly basis, Total Debt rose 3.26% year-over-year to $127.1 million in Q4 2022; TTM through Dec 2022 was $127.1 million, a 3.26% increase from a year earlier, with the FY2022 full-year figure at $128.4 million, up 3.34% from the prior year.
  • Total Debt grew to $127.1 million in Q4 2022 per OCS's latest filing, from $123.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $127.1 million in Q4 2022 and bottomed at $123.1 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 110.96 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 959.06 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 127.10 Mn
Dec 31, 2021 123.09 Mn